

Refractory Canine Immune-Mediated Hemolytic Anemia

Michael J. Day, BSc, BVMS (Hons), PhD, DSc, DiplECVP, FASM, FRCPath, FRCVS University of Bristol

Barbara Kohn, Dr med vet, PD, DiplECVIM Freie Universität Berlin





REFERENCES

- 1. Treatment of canine idiopathic immune-mediated haemolytic anaemia with mycophenolate mofetil and glucocorticoids: 30 cases (2007 to 2011). Wang A, Smith JR, Creevy KE. *J Small Anim Pract* 54(8):399-404, 2013.
- A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin. Spurlock NK, Prittie JE. JVECC 21(5):471-483. 2011.
- Canine immune-mediated hemolytic anemia. Day MJ. Clin Brief 10(10):53-57, 2012

SUGGESTED READING

Immunosuppressive therapy for canine immune-mediated hemolytic anemia. Al-Ghazlat S. Compend Contin Educ Vet 31[1]:33-41, 44, 2009.

Systematic review of evidence relating to the treatment of immune-mediated hemolytic anemia in dogs. Swann JW, Skelly BJ. JVIM 27(1):1-9, 2013.

Treatment of immune-mediated hemolytic anemia with individually adjusted heparin dosing in dogs. Helmond SE, Polzin DJ, Armstrong PJ, et al. *JVIM* 24(3):597-609, 2010.

Use of human immunoglobulin in addition to glucocorticoids for the initial treatment of dogs with immune-mediated hemolytic anemia. Whelan MF, O'Toole TE, Chan DL, et al. J Vet Emerg Crit Care (San Antonio) 19(2):158-164, 2009.

MICHAEL J. DAY, BSc, BVMS (Hons), PhD, DSc, DiplECVP, FASM, FRCPath, FRCVS,

is professor of veterinary pathology at University of Bristol. He is senior vice president of BSAVA and vice president of the WSAVA Foundation, in addition to being chairman of the WSAVA Vaccination Guidelines Group and One Health Committee.

BARBARA KOHN, Dr med vet, PD, DiplECVIM, is professor of small animal internal medicine and director of the small animal clinic of the Faculty of Veterinary Medicine, Freie Universität Berlin.

DIC = disseminated intravascular coagulation, IMHA = immune-mediated hemolytic anemia